-
Researchers develop AI technique to treat cancer
biospectrumasia
August 14, 2018
The new "self-learning" machine-learning technique could make the dosing regimen less toxic but still effective
-
Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD Join Lixte Biotechnology’s Board of Directors
biospectrumasia
August 13, 2018
Dr. Yen also founded philanthropic organizations aimed at serving the global cancer community and holds membership in numerous professional societies. He serves on the boards of Fulgent Genetics and Tanvex BioPharma Inc.
-
Pfizer drops diabetes and cancer drugs from clinical pipeline
fiercebiotech
August 01, 2018
Pfizer has culled Type 1 diabetes and cancer drugs from its early-phase?pipeline?(PDF). The actions affect anti-IL7R antibody PF-06342674 and third-generation, mutant-selective EGFR tyrosine kinase inhibitor PF-06747775.
-
JCVI backs HPV jab for boys
pharmatimes
July 25, 2018
The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
-
BI snaps up OSE’s novel checkpoint inhibitor
pharmatimes
July 18, 2018
Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours.
-
NICE approves treatment for rare and deadly childhood cancer
pharmafile
July 17, 2018
NICE has recommended that monoclonal antibody dinutuximab beta be used in treating high-risk neuroblastoma – a rare and deadly form of cancer that mainly affects young children.
-
Lilly takes back cancer drug with AurKa buy
pharmatimes
July 11, 2018
Eli Lilly has unveiled a deal to buy AurKa Pharma, bringing back in-house experimental fisrt-in-class cancer drug AK-01.
-
End-of-Life Care Depends on Doctor
drugs
July 10, 2018
The amount spent on end-of-life care for?cancer?patients varies widely across the United States, and is largely influenced by doctor preferences, new research finds.
-
'Kiss of death' cancer
worldpharmanews
July 05, 2018
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy.
-
How targeting metabolism can defeat cancer stem cells
worldpharmanews
July 05, 2018
Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
